PURPOSE: To investigate the functional involvement of caspase-4 in human retinal pigment epithelial (hRPE) cells. METHODS: Expression and activation of caspase-4 in hRPE cells were measured after stimulation with proinflammatory agents IL-1beta (2 ng/mL), TNF-alpha (20 ng/mL), lipopolysaccharide (1000 ng/mL), interferon-gamma (500 U/mL), or monocyte coculture in the absence or presence of immunomodulating agent cyclosporine (3 or 30 ng/mL), dexamethasone (10 microM), or IL-10 (100 U/mL) and endoplasmic reticulum (ER) stress inducer thapsigargin (25 nM) or tunicamycin (3 or 10 microM). The onset of ER stress was determined by expression of GRP78. The involvement of caspase-4 in inflammation and apoptosis was further examined by treating the cells with caspase-4 inhibitor Z-LEVD-fmk, caspase-1 and -4 inhibitor Z-YVAD-fmk, and pan-caspase inhibitor Z-VAD-fmk. RESULTS: Caspase-4 mRNA expression and protein activation were induced by all the proinflammatory agents and ER stress inducers tested in this study. Caspase-4 activation was blocked or reduced by dexamethasone and IL-10. Elevated ER stress by proinflammatory agents and ER stress inducers was shown by increased expression of the ER stress marker GRP78. The induced caspase-4 and caspase-3 activities by tunicamycin and the stimulated IL-8 protein expression by IL-1beta were markedly reduced by caspase-4 inhibitor Z-LEVD-fmk. Although caspase-4 inhibitor Z-LEVD-fmk and caspase-1 and -4 inhibitor Z-YVAD-fmk reduced tunicamycin-induced hRPE apoptotic cell death by 59% and 86%, respectively, pan-caspase inhibitor Z-VAD-fmk completely abolished the induced apoptosis. CONCLUSIONS: Caspase-4 is dually involved in hRPE proinflammatory and proapoptotic responses. Various proinflammatory stimuli and ER stress induce hRPE caspase-4 mRNA synthesis and protein activation. ER stress-induced hRPE cell death is caspase and, in part, caspase-4 dependent.
PURPOSE: To investigate the functional involvement of caspase-4 in humanretinal pigment epithelial (hRPE) cells. METHODS: Expression and activation of caspase-4 in hRPE cells were measured after stimulation with proinflammatory agents IL-1beta (2 ng/mL), TNF-alpha (20 ng/mL), lipopolysaccharide (1000 ng/mL), interferon-gamma (500 U/mL), or monocyte coculture in the absence or presence of immunomodulating agent cyclosporine (3 or 30 ng/mL), dexamethasone (10 microM), or IL-10 (100 U/mL) and endoplasmic reticulum (ER) stress inducer thapsigargin (25 nM) or tunicamycin (3 or 10 microM). The onset of ER stress was determined by expression of GRP78. The involvement of caspase-4 in inflammation and apoptosis was further examined by treating the cells with caspase-4 inhibitor Z-LEVD-fmk, caspase-1 and -4 inhibitor Z-YVAD-fmk, and pan-caspase inhibitor Z-VAD-fmk. RESULTS:Caspase-4 mRNA expression and protein activation were induced by all the proinflammatory agents and ER stress inducers tested in this study. Caspase-4 activation was blocked or reduced by dexamethasone and IL-10. Elevated ER stress by proinflammatory agents and ER stress inducers was shown by increased expression of the ER stress marker GRP78. The induced caspase-4 and caspase-3 activities by tunicamycin and the stimulated IL-8 protein expression by IL-1beta were markedly reduced by caspase-4 inhibitor Z-LEVD-fmk. Although caspase-4 inhibitor Z-LEVD-fmk and caspase-1 and -4 inhibitor Z-YVAD-fmk reduced tunicamycin-induced hRPE apoptotic cell death by 59% and 86%, respectively, pan-caspase inhibitor Z-VAD-fmk completely abolished the induced apoptosis. CONCLUSIONS:Caspase-4 is dually involved in hRPE proinflammatory and proapoptotic responses. Various proinflammatory stimuli and ER stress induce hRPEcaspase-4 mRNA synthesis and protein activation. ER stress-induced hRPE cell death is caspase and, in part, caspase-4 dependent.
Authors: P F Lopez; H E Grossniklaus; H M Lambert; T M Aaberg; A Capone; P Sternberg; N L'Hernault Journal: Am J Ophthalmol Date: 1991-12-15 Impact factor: 5.258
Authors: Kan Koizumi; Vassiliki Poulaki; Sven Doehmen; Gerhard Welsandt; Sven Radetzky; Alexandra Lappas; Norbert Kociok; Bernd Kirchhof; Antonia M Joussen Journal: Invest Ophthalmol Vis Sci Date: 2003-05 Impact factor: 4.799
Authors: M Wang; P Wang; Y Q Liu; J L Peng; X P Zhao; S Wu; F R He; X Wen; Y Li; G X Shen Journal: Clin Exp Immunol Date: 2007-10-23 Impact factor: 4.330
Authors: V M Elner; R M Strieter; M A Pavilack; S G Elner; D G Remick; J M Danforth; S L Kunkel Journal: Am J Pathol Date: 1991-11 Impact factor: 4.307
Authors: Maya Saleh; John P Vaillancourt; Rona K Graham; Matthew Huyck; Srinivasa M Srinivasula; Emad S Alnemri; Martin H Steinberg; Vikki Nolan; Clinton T Baldwin; Richard S Hotchkiss; Timothy G Buchman; Barbara A Zehnbauer; Michael R Hayden; Lindsay A Farrer; Sophie Roy; Donald W Nicholson Journal: Nature Date: 2004-05-06 Impact factor: 49.962
Authors: Rebecca N Bauer; Luisa E Brighton; Loretta Mueller; Zhidan Xiang; Julia E Rager; Rebecca C Fry; David B Peden; Ilona Jaspers Journal: J Allergy Clin Immunol Date: 2012-10 Impact factor: 10.793
Authors: Zong-Mei Bian; Susan G Elner; Hemant Khanna; Carlos A Murga-Zamalloa; Suresh Patil; Victor M Elner Journal: Invest Ophthalmol Vis Sci Date: 2011-11-07 Impact factor: 4.799